Coherus Oncology, Inc. (CHRS)
1.41
-0.05
(-3.42%)
USD |
NASDAQ |
Aug 28, 16:00
1.40
-0.01
(-0.71%)
After-Hours: 20:00
Coherus Oncology Net Income (Quarterly) : -33.35M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -33.35M |
| March 31, 2026 | -36.94M |
| December 31, 2025 | -46.35M |
| September 30, 2025 | -44.52M |
| June 30, 2025 | -44.86M |
| March 31, 2025 | -47.40M |
| December 31, 2024 | -46.09M |
| September 30, 2024 | -47.60M |
| June 30, 2024 | -54.85M |
| March 31, 2024 | -68.04M |
| December 31, 2023 | -79.65M |
| September 30, 2023 | -39.64M |
| June 30, 2023 | -42.87M |
| March 31, 2023 | -75.73M |
| December 31, 2022 | -58.87M |
| September 30, 2022 | -86.65M |
| June 30, 2022 | -50.15M |
| March 31, 2022 | -96.08M |
| December 31, 2021 | -45.72M |
| September 30, 2021 | -38.53M |
| June 30, 2021 | -29.90M |
| March 31, 2021 | -172.95M |
| December 31, 2020 | 9.708M |
| September 30, 2020 | 27.93M |
| June 30, 2020 | 59.03M |
| Date | Value |
|---|---|
| March 31, 2020 | 35.57M |
| December 31, 2019 | 39.23M |
| September 30, 2019 | 47.04M |
| June 30, 2019 | 23.57M |
| March 31, 2019 | -20.00M |
| December 31, 2018 | -62.60M |
| September 30, 2018 | -58.83M |
| June 30, 2018 | -43.68M |
| March 31, 2018 | -44.30M |
| December 31, 2017 | -49.07M |
| September 30, 2017 | -58.99M |
| June 30, 2017 | -55.40M |
| March 31, 2017 | -74.82M |
| December 31, 2016 | -75.94M |
| September 30, 2016 | 83.84M |
| June 30, 2016 | -70.15M |
| March 31, 2016 | -65.54M |
| December 31, 2015 | -52.58M |
| September 30, 2015 | -71.48M |
| June 30, 2015 | -59.03M |
| March 31, 2015 | -40.84M |
| December 31, 2014 | -29.02M |
| September 30, 2014 | -7.914M |
| June 30, 2014 | -25.07M |
| March 31, 2014 | -25.17M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Enanta Pharmaceuticals, Inc. | -19.50M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 14.31M |
| Total Expenses (Quarterly) | 47.65M |
| EPS Diluted (Quarterly) | -0.1312 |
| Enterprise Value | 166.67M |
| Gross Profit Margin (Quarterly) | 64.33% |
| Profit Margin (Quarterly) | -233.1% |
| Earnings Yield | -72.43% |
| Normalized Earnings Yield | -71.52 |